Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Steven M. Horwitz, MD, Neha Mehta-Shah, MD, Barbara Pro, MD, Eric D Jacobsen, MD, Carla Casulo, Jonathan E. Brammer, MD, Jeff Haney, Hagop Youssoufian, MD, David T. Weaver, PhD, Michael Baglio, PharmD, Jasminder Soto, Narayana Narasimhan, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 1567.

https://doi.org/10.1182/blood-2019-121401

Published: 2019

Journal Articles

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Jennifer R Brown, MD PhD, Kam Sprott, PhD, Santosh Reddy, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4312.

https://doi.org/10.1182/blood-2019-122491

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model

Shih-Shih Chen, PhD, Jeffery Lorne Kutok, MD PhD, Gerardo Ferrer, PhD, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, MSCR, Jacqueline C Barrientos, MD MS, David T. Weaver, PhD, Jonathan A Pachter, PhD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 4420.

https://doi.org/10.1182/blood-2018-99-109853

Published: 2018

Journal Articles

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Carole B. Miller, MD, Scott A. Tetreault, MD, Kirit M. Ardeshna, MBBChir, NgocDiep Le, MD PhD, Jonathan A. Pachter, PhD, Kam Sprott, PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2018-99-117903

Published: 2018

Journal Articles

Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO TM Study

Jennifer R. Brown, MD PhD, Ian W. Flinn, MD PhD, Matthew S. Davids, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Marco Montillo, MD, Zsolt Nagy, MD PhD, Julio Delgado, MD, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Ulrich Jaeger, MD, Paolo Ghia, MD PhD, Stephan Stilgenbauer, Carol Moreno, MD PhD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, Kam Sprott, PhD, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Florence Cymbalista, MD PhD

Blood (2018) 132 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2018-99-114251

Published: 2018

Journal Articles

The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

Matthew S. Davids, MD, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Marco Montillo, MD, James Essell, MD, Nicole Lamanna, MD, Zsolt Nagy, MD PhD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Stephan Stilgenbauer, Paolo Ghia, MD PhD, Julio Delgado, MD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Ulrich Jaeger, MD

Blood (2018) 132 (Supplement 1): 3140.

https://doi.org/10.1182/blood-2018-99-117521

Published: 2018

Journal Articles

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML

Xiangmeng Wang, PhD, Po Yee Mak, Hong Mu, MD PhD, Wenjing Tao, PhD, Jonathan A Pachter, PhD, David T Weaver, PhD, Bing Xu, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2017) 130 (Supplement 1): 2653.

https://doi.org/10.1182/blood.V130.Suppl_1.2653.2653

Published: 2017

Journal Articles

The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model

Jonathan A Pachter, PhD, David T Weaver, PhD

Blood (2017) 130 (Supplement 1): 1541.

https://doi.org/10.1182/blood.V130.Suppl_1.1541.1541

Published: 2017

Journal Articles

Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML

Xiangmeng Wang, Po Yee Mak, MPhil, Hong Mu, MD PhD, Xuejie Jiang, Duncan Mak, BSc, MPhil, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Bing Xu, PhD, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2016) 128 (22): 1574.

https://doi.org/10.1182/blood.V128.22.1574.1574

Published: 2016

Journal Articles

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Mark B Meads, PhD, Bin Fang, PhD, Linda Mathews, Jennifer Gemmer, MS, Liang Nong, MD, Ismael Rosado-Lopez, Tuan Nguyen, Jennifer E. Ring, William Matsui, MD, Robert MacLeod, PhD, David T. Weaver, PhD, Jonathan A. Pachter, PhD, Lori A. Hazlehurst, PhD, John M. Koomen, PhD, Kenneth H. Shain, MD PhD

Blood (2015) 126 (23): 3008.

https://doi.org/10.1182/blood.V126.23.3008.3008

Published: 2015

Journal Articles

Efficacy of Focal Adhesion Kinase Inhibition in Combination with Dasatinib in BCR-ABL1 Acute Lymphoblastic Leukemia

Michelle L. Churchman, PhD, Luke Jones, BSc(Hons), Kathryn Evans, BSc(Hons), Jennifer Richmond, BSc(Hons), Irina M Shapiro, PhD, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Peter J Houghton, PhD, Malcolm A. Smith, MD PhD, Richard B Lock, PhD, Charles G. Mullighan, MBBS, MSc, MD

Blood (2015) 126 (23): 3766.

https://doi.org/10.1182/blood.V126.23.3766.3766

Published: 2015

Journal Articles

Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1 Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy of High-Risk B-ALL

Ila Joshi, PhD, Nilamani Jena, PhD, Toshimi Yoshida, PhD, Leto Paraskevopoulou, BS, Zhihong Zhang, PhD, Zhong-Ying Liu, MDPhD, Shane Korber, Daniela S. Krause, MD, Irina M. Shapiro, PhD, David T. Weaver, PhD, Jonathan A. Pachter, PhD, Elisabeth M. Paietta, PhD, Richard A. Van Etten, MDPhD, Katia Georgopoulos, PhD

Blood (2014) 124 (21): 285.

https://doi.org/10.1182/blood.V124.21.285.285

Published: 2014

Journal Articles

VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo

Winnie F. Tam, PhD, Jennifer E. Ring, Anthony F. Trombino, PhD, David T. Weaver, PhD, Jonathan A. Pachter, PhD, Mahesh Padval, PhD, Qunli Xu, PhD

Blood (2014) 124 (21): 982.

https://doi.org/10.1182/blood.V124.21.982.982

Published: 2014

NARROW

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO TM Study

The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML

The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model

Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Efficacy of Focal Adhesion Kinase Inhibition in Combination with Dasatinib in BCR-ABL1 Acute Lymphoblastic Leukemia

Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1 Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy of High-Risk B-ALL

VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only